Something new every day: Defining innovation and innovativeness in drug therapy

Journal of Ambulatory Care Management

Volumn 31, Issue 1, 2008, Pages 65-68

  Aronson, Jeffrey K ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Benefit to harm balance; Drug therapy; Innovation; Innovativeness

Indexed keywords

NEW DRUG;

ARTICLE; DRUG THERAPY; HUMAN; MASS COMMUNICATION; STANDARD; UNITED KINGDOM;

DIFFUSION OF INNOVATION; DRUG THERAPY; DRUGS, INVESTIGATIONAL; GREAT BRITAIN; HUMANS;

EID: 37749048756     PISSN: 01489917     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.JAC.0000304100.38120.b2     Document Type: Article

References (12)

1. Apolone, G., & Patarnello, F. (2007). The value of a drug: From payment to the National Health Service via Karl Marx. The Journal of Ambulatory Care Management, 31(1) 52-55.
2. Appleby, J., Devlin, N., & Parkin, D. (2007). NICE'S cost effectiveness threshold. BMJ, 335, 358-359.
3. Aronson, J. K. (2005). Drug development: More science, more education. British Journal of Clinical Pharmacology, 59, 377-378.
4. Baber, N. S., Ritter, J. M., & Aronson, J. K. (2004). Medicines regulation and clinical pharmacology. British Journal of Clinical Pharmacology, 58, 569-570.
5. Cohen, F. J. (2005). Macro trends in pharmaceutical innovation. Nature Reviews Drug Discovery, 4, 78-84.
6. Department of Trade and Industry, HM Treasury, Department for Education and Skills. (2002, July). Investing in innovation. A. strategy for science, engineering and technology. London: The Stationery Office limited. Retrieved October 3, 2007, from www.hmtreasury.gov.uk/spending_review/spend_sr02/ spend_sr02_science.cfm
7. Erice Group. (2007, October 8). Erice statement on drug innovation. British Journal of Clinical Pharmacology. Epub ahead of print.
8. Food and Drug Administration. (2004, March). Challenge and opportunity on the critical path to new medical products. Retrieved October 3, 2007, from http://www.fda.gov/oc/initiatives/criticalpath/ whitepaper.html
9. Motola, D., De Ponti, F., Poluzzi, E., Martini, N., Rossi, P., Chiara Silvani, M., et al. (2006). An update on the first decade of the European centralized procedure: How many innovative drugs? British Journal of Clinical Pharmacology, 62, 610-616.
10. Motola, D., De Ponti, F., Rossi, P., Martini, N., & Montanaro, N. (2005). Therapeutic innovation in the European Union: Analysis of the drugs approved by the EMEA between 1995 and 2003. British Journal of Clinical Pharmacology, 59, 475-478.
11. National Governors Association. (2002). Innovation America. Investing in innovation. National Governors Association Center for Best Practices & the Pew Center on the States. Retrieved October 3, 2007, from www.nga.org/Files/pdf/0707INNOVATIONINVEST.PDF
12. Sorites paradox. (2007). In Stanford encyclopedia of philosophy. Retrieved October 3, 2007, from http://plato.stanford.edu/entries/sorites- paradox